Arbour and collaborators identified a molecular subtype of KRAS-mutant NSCLC with co-mutations in KEAP1 and NFE2L2 genes, where patients had significantly shorter overall survival (OS), and a reduced duration of platinum-based chemotherapy response compared to other KRAS-mutant NSCLC patients [70]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.